Provided by Tiger Trade Technology Pte. Ltd.

Supernus Pharmaceuticals

42.38
+0.20000.47%
Post-market: 42.380.00000.00%16:10 EDT
Volume:738.47K
Turnover:31.39M
Market Cap:2.46B
PE:-22.14
High:43.15
Open:42.47
Low:41.88
Close:42.18
52wk High:59.68
52wk Low:40.51
Shares:58.04M
Float Shares:51.67M
Volume Ratio:1.23
T/O Rate:1.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9145
EPS(LYR):-0.6829
ROE:-10.49%
ROA:0.39%
PB:2.39
PE(LYR):-62.06

Loading ...

Addex Regains Global Rights to GABAB PAM Assets from Indivior

Reuters
·
Sep 25

Indivior Sets USD 8.13 Special Dividend Tied to Supernus Merger Closing

Reuters
·
Sep 17

Supernus Pharmaceuticals to Participate in September Investor Conferences

GlobeNewswire
·
Sep 03

Supernus Pharmaceuticals (SUPN) On Chloe Kim ADHD Push And Whether Undervalued Looks Priced In

Simply Wall St.
·
Sep 02

Inventiva Names Chris Benecchi Chief Operating Officer

Reuters
·
Sep 01

Supernus Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

U.S. Stocks on the MOVE -Visa, Bowhead Specialty, Micron

Reuters
·
Aug 03

UPDATE: Supernus Pharmaceuticals Q2 Adj. EPS $0.53 Beats $0.42 Estimate

Benzinga Earnings
·
Aug 03

Supernus, Indivior Merge to Strengthen Neuroscience Drug Portfolio

Reuters
·
Aug 03

Supernus Pharmaceuticals Swings to Q2 Net Loss, Revenue Rises; Fiscal 2026 Revenue Outlook Raised

MT Newswires Live
·
Aug 03

Indivior Pharmaceuticals, Supernus Pharmaceuticals to Combine in All-Stock Merger

MT Newswires Live
·
Aug 03

Earnings Flash (SUPN) Supernus Pharmaceuticals Posts Q2 Net Loss $1.01 a Share, vs. FactSet Est of $0.04 EPS

MT Newswires Live
·
Aug 03

Supernus Pharmaceuticals Q2 EPS USD -1.01

Reuters
·
Aug 03

Supernus Q2 FY26 Net Loss Widens to $58.4 Million; Revenue Rises 32% to $219.1 Million

Reuters
·
Aug 03

Supernus Pharmaceuticals Shares Rise 5.3% Premarket After Co to Merge with Indivior Pharmaceuticals

THOMSON REUTERS
·
Aug 03

Supernus Pharmaceuticals Q2 Product Sales USD 165.7 Million

THOMSON REUTERS
·
Aug 03

Supernus Pharmaceuticals Outlook FY Revenue USD 860-890 Million

THOMSON REUTERS
·
Aug 03

Supernus Announces Second Quarter 2026 Financial Results

THOMSON REUTERS
·
Aug 03

Supernus, Indivior Agree All-Stock Merger, Combined Firm to Trade as Supernus on NASDAQ

Reuters
·
Aug 03

Supernus Pharmaceuticals - Stockholders Will GET 1.5401 Common Shares of Indivior Pharmaceuticals for Each Share of Supernus Pharmaceuticals They Own

THOMSON REUTERS
·
Aug 03